BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Natalicchio A, Faggiano A, Zatelli MC, Argentiero A, D'Oronzo S, Marrano N, Beretta GD, Acquati S, Adinolfi V, Di Bartolo P, Danesi R, Ferrari P, Gori S, Morviducci L, Russo A, Tuveri E, Montagnani M, Gallo M, Silvestris N, Giorgino F. Metabolic disorders and gastroenteropancreatic-neuroendocrine tumors (GEP-NETs): How do they influence each other? An Italian Association of Medical Oncology (AIOM)/ Italian Association of Medical Diabetologists (AMD)/ Italian Society of Endocrinology (SIE)/ Italian Society of Pharmacology (SIF) multidisciplinary consensus position paper. Crit Rev Oncol Hematol 2021;:103572. [PMID: 34954047 DOI: 10.1016/j.critrevonc.2021.103572] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
Number Citing Articles
1 Cantone MC, Gaudenzi G, Carra S, Saronni D, Dicitore A. Obesity and GEP-NET: which to hit first? Minerva Med 2022;113:913-5. [PMID: 36695409 DOI: 10.23736/S0026-4806.22.08314-8] [Reference Citation Analysis]
2 Lan X, Fazio N, Abdel-rahman O. Exploring the Relationship between Obesity, Metabolic Syndrome and Neuroendocrine Neoplasms. Metabolites 2022;12:1150. [DOI: 10.3390/metabo12111150] [Reference Citation Analysis]
3 Scherübl H. Metabolisches Syndrom und gastrointestinale Krebsvorsorge. Z Gastroenterol 2022. [DOI: 10.1055/a-1959-3829] [Reference Citation Analysis]
4 Pavlidis ET, Pavlidis TE. Molecular factors, diagnosis and management of gastrointestinal tract neuroendocrine tumors: An update. World J Clin Cases 2022; 10(27): 9573-9587 [DOI: 10.12998/wjcc.v10.i27.9573] [Reference Citation Analysis]